Dry powder aerosol containing muco-inert particles for excipient enhanced growth pulmonary drug delivery.

Abstract Tenacious sputum poses a critical diffusion barrier for aerosol antibiotics used to treat cystic fibrosis (CF) lung infection. We conducted a proof-of-concept study using dense poly(ethylene glycol) coated polystyrene nanoparticles (PS-PEG NPs) as model muco-inert particles (MIP) formulated as a powder using an excipient enhanced growth (EEG) strategy, aiming to minimize extrathoracic airway loss, maximize deposition in the airway and further overcome the sputum barrier in the CF lungs. The EEG aerosol formulation containing PS-PEG MIP was prepared by spray drying and produced discrete spherical particles with geometric diameter of approximately 2 μm; and > 80% of the powder dose was delivered from a new small-animal dry powder inhaler (DPI). The MIP released from the EEG aerosol had human airway mucus and CF sputum diffusion properties comparable to the suspension formulation. These properties make this formulation a promising pulmonary drug delivery system for CF lung infections.